Operationalizing ADC Clinical Trials: Best Practices for Success

As the oncology landscape evolves, antibody-drug conjugates (ADCs) have emerged as one of the most promising modalities in targeted cancer therapy. With 15 ADCs approved globally and more than 400 in development, the opportunity to advance patient outcomes has never been greater¹. Yet, success in ADC trials requires a deep understanding of the safety profile and the operational complexities that accompany these transformative therapies.

This webinar will explore strategies to optimize ADC clinical trial execution. Attendees will learn how to design protocols geared towards dose optimization by applying Project Optimus principles, navigate global site selection and implement appropriate site training using ADC-specific patient education and toxicity management tools. This webinar will also highlight how biomarker-driven enrollment, streamlined screening, toxicity management and reduced procedural burden can enhance recruitment and retention while improving overall patient experience.

Register for this webinar to learn how ADC clinical trials can be optimized through operational excellence and thoughtful study design.

Sources:

1. Wang, R., Hu, B., Pan, Z. et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol 18, 51 (2025). https://doi.org/10.1186/s13045-025-01704-3

Speakers

Ashley Herrick, PhD, Vice President, Oncology Program Strategy, Premier Research

Dr. Ashley Herrick provides strategic planning, coordination, knowledge and expertise for oncology projects. She has more than 15 years of experience in oncology clinical trial oversight and drug development. She has experience across all phases of clinical trials, with a keen interest and deep knowledge of early-phase and first-in-man studies. She has led numerous global clinical trials and has experience with strategic management, study oversight, study start-up, efficient enrollment and study close-out/CSR development.

Prior to joining Premier Research, Dr. Herrick was Director of Operational Strategy Management for a mid-sized CRO overseeing the strategic planning for studies. She also supported their Oncology Site Network and oversaw a biomarker-driven patient-matching group. She has served as Project Director, Project Manager and CRA throughout her years working in the CRO industry and has devoted her entire career to oncology research. Prior to joining the CRO industry, she worked as a Program Manager for the largest Phase I clinical trial unit in the country at MD Anderson Cancer Center, where she oversaw more than 50 industry-sponsored and investigator-led Phase I clinical trials.

Dr. Herrick holds a PhD in Molecular and Cellular Biology with a focus on hematologic malignancies from Baylor College of Medicine. She is CCRP-certified and a member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). She is an active volunteer with the Leukemia and Lymphoma Society (LLS).

Message Presenter

Jordan Curry, Senior Project Director, Oncology, Premier Research

With over 13 years of global clinical research experience, Jordan Curry is a delivery-focused leader specializing in oncology, hematology and rare diseases. Since joining Premier Research as Senior Project Director, he has provided both strategic oversight and operational leadership. He works closely with sponsors from early engagement through trial execution, playing a key role in program delivery, strategic planning and ensuring cross-functional alignment across all phases of development.

Prior to Premier, Jordan held project management roles of increasing seniority within several mid- to large-sized CROs. He led multidisciplinary teams and oversaw complex oncology and hematology trials, supporting both large-scale programs and agile biotech portfolios. Most recently, he served as a Project Director within a dedicated global oncology division.

Jordan holds a BSc (Hons) in Human Biology and has built his career leading global oncology trials at top CROs, including IQVIA, Syneos Health and Premier Research.

Message Presenter